A Phase 1/2 interventional study of LDE225 in Medulloblastoma, Rhabdomyosarcoma and Neuroblastoma, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in 6 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2017-03-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.
Among the 245 studies in Medulloblastoma with a site in United States, this one is the 43rd largest by enrollment of the 215 interventional ones that give a count, is one of 5 that started in 2011, is one of 22 in phase 1/2, and was the 116th registered.
317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.
Browse Medulloblastoma studies →26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:
Robbie Majzner · Sites in United States
Ages 2–21
Sabine Mueller, MD, PhD · Sites in United States
Ages 1–25
St. Jude Children's Research Hospital · Sites in United States
Ages 10–25
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 3–22
University of Florida · Sites in United States
Ages 4–39
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 87 · Phase 3 11 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 31 across 255 interventional studies indexed under Medulloblastoma.
Median enrollment 30 across the 215 interventional studies, 139 across the 15 observational. Of the 181 that completed or were terminated, 57 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 245 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Medulloblastoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Medulloblastoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT06701812H. Lee Moffitt Cancer Center and Research InstituteDigoxin Medulloblastoma Study | 2027-02 |
| NCT04541082Jazz PharmaceuticalsPhase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | 2027-03-31 |
| NCT04185038Seattle Children's HospitalStudy of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | 2027-05 |
Add all 11 to your calendar (.ics) → With an account.
Among the 245 studies in Medulloblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway.
Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric dose.
Drug: LDE225
Pediatric dose.
Drug: LDE225
Pediatric dose.
Drug: LDE225
Pediatric dose.
Drug: LDE225
Adult dose
Drug: LDE225
LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Also known as: sonidegib
Number of Participants With Dose-limiting Toxicities (DLT) in Phase I
DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications. DLT included any grade 3 or 4 clinically-evident toxicity, Hematology: ≥ CTCAE grade 3 neutropenia (ANC \<1.0x10\^9/L); ≥ CTCAE grade 3 thrombocytopenia (platelets \<50x10\^9/L); ≥ CTCAE grade 3 anemia (Hgb \<80 g/L); Febrile neutropenia (ANC \<1x10\^9/L, fever ‡ 38.5°C), Renal: ≥ CTCAE grade 3 serum creatinine (\>3xULN), Hepatic: ≥ CTCAE grade 3 total bilirubin (\>3xULN); ≥ 10xULN ALT elevation; grade 2 total bilirubin (\>1.5ULN) together with ≥ grade 3 ALT elevation (\>5xULN), Cardiac: ≥ CTCAE grade 3, Other AEs: ≥ CTCAE grade 3 vomiting or nausea despite optimal antiemetic therapy, diarrhea despite optimal antidiarrheal treatment.
Time frame: Baseline, End of dose escalation part (Day 42)
Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose-limiting toxicity (DLT), based on Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications.k
Time frame: Baseline, End of dose escalation part (Day 42)
Percentage of Participants With Objective Response Rate (ORR) by Treatment
The tumor response to the sonidegib treatment was measured by ORR. The ORR was defined as the percentage of participants with partial response or complete response as their best overall response. Participants with stable disease, progressive disease tumor assessment were considered as non-responders. Response evaluation criteria was gadolinium chelate-enhanced brain tumor magnetic resonance imaging (Gd-MRI) for Medulloblastoma and central nervous system (CNS) tumors and response evaluation criteria in solid tumors (RECIST) version 1.0 for non-CNS tumors assessed by MRI. Complete Response (CR), Progressive Disease (PD) and Incomplete Response/Stable Disease (SD) were defined as disappearance of all non-target lesions, unequivocal progression of existing non-target lesions and Neither CR nor PD, respectively.
Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and Death During the Study
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs were defined as AEs that were suspected to be related to study treatment as per investigator. On-treatment deaths were deaths which occurred up to 30 days after last date of study treatment.
Time frame: Baseline (start of study treatment) up to End of treatment (Within 14 days of last dose)
Area Under the Drug Concentration Time Curve From Time Zero to 24 Hours After Dosing (AUC0-24h) of Sonidegib in Phase I
AUC(0-24h) was defined as the area under the drug concentration time curve calculated using linear trapezoidal summation from time zero to 24 hours after dosing.
Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sonidegib in Phase I
Tmax was defined as the time required to reach maximum observed plasma concentration. Tmax was directly determined from the raw plasma concentration time data.
Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Maximum Observed Plasma Concentration (Cmax) of Sonidegib in Phase I
Maximum observed plasma concentration following drug administration was calculated from the raw plasma concentration time data.
Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status
ORR was determined in the participants with mutations on Hh gene (Hh positive) and the participants without mutations on Hh gene (Hh negative).
Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Duration of Response by Treatment
Duration of overall response (complete response (CR) or partial response (PR)) was calculated for those participants whose best overall response was CR or PR. The start date was the date of the first documented tumor response (CR or PR) and the end date was the date of the event defined as the first documented progression or death due to underlying cancer or after the same treatment line. If a participant did not have a progression or death, the duration of response was censored at the date of last adequate tumor assessment in that treatment line.
Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
The study was conducted at 14 centers in 6 countries.
| Milestone | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| Started | 11 | 16 | 11 | 21 | 0 |
| Completed | 3 | 7 | 7 | 10 | 0 |
| Not completed | 8 | 9 | 4 | 11 | 0 |
| Withdrew: Protocol violation | 0 | 3 | 1 | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 | 1 | 7 | 0 |
| Withdrew: Administrative problems | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Disease progression | 5 | 4 | 1 | 3 | 0 |
| Milestone | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1 | 16 |
| Completed | 0 | 0 | 0 | 0 | 5 |
| Not completed | 0 | 0 | 0 | 1 | 11 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 8 |
DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications. DLT included any grade 3 or 4 clinically-evident toxicity, Hematology: ≥ CTCAE grade 3 neutropenia (ANC \<1.0x10\^9/L); ≥ CTCAE grade 3 thrombocytopenia (platelets \<50x10\^9/L); ≥ CTCAE grade 3 anemia (Hgb \<80 g/L); Febrile neutropenia (ANC \<1x10\^9/L, fever ‡ 38.5°C), Renal: ≥ CTCAE grade 3 serum creatinine (\>3xULN), Hepatic: ≥ CTCAE grade 3 total bilirubin (\>3xULN); ≥ 10xULN ALT elevation; grade 2 total bilirubin (\>1.5ULN) together with ≥ grade 3 ALT elevation (\>5xULN), Cardiac: ≥ CTCAE grade 3, Other AEs: ≥ CTCAE grade 3 vomiting or nausea despite optimal antiemetic therapy, diarrhea despite optimal antidiarrheal treatment.
| participants | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 |
|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLT) in Phase I | 0 | 1 | 0 | 0 |
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose-limiting toxicity (DLT), based on Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications.k
| mg/m^2 | All Participants |
|---|---|
| Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use | 680 |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs were defined as AEs that were suspected to be related to study treatment as per investigator. On-treatment deaths were deaths which occurred up to 30 days after last date of study treatment.
| participants | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| AEs | 11 | 16 | 11 | 22 | 16 |
| AEs suspected to be drug related | 8 | 13 | 9 | 14 | 13 |
| AEs leading to discontinuation | 1 | 1 | 1 | 1 | 3 |
| On-treatment deaths | 2 | 2 | 1 | 8 | 2 |
| SAEs | 5 | 8 | 4 | 14 | 5 |
AUC(0-24h) was defined as the area under the drug concentration time curve calculated using linear trapezoidal summation from time zero to 24 hours after dosing.
| nanograms*hours/millilitres (ng*hr/mL) | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 |
|---|---|---|---|---|
| Cycle 1/Day 1 (n=11, 15, 11, 19) | 1981.56 ± 736.928 | 2194.29 ± 1592.396 | 5309.44 ± 3247.088 | 5117.61 ± 2658.133 |
| Cycle 1/Day 22 (n=9, 14, 9, 15) | 10589.53 ± 4163.192 | 15431.43 ± 10433.35 | 17753.32 ± 11551.57 | 32622.67 ± 11670.63 |
Tmax was defined as the time required to reach maximum observed plasma concentration. Tmax was directly determined from the raw plasma concentration time data.
| hours | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 |
|---|---|---|---|---|
| Cycle 1/Day 1 (n=11, 15, 10, 17) | 3.98 (1.07 to 6.75) | 2.03 (1 to 7) | 2.92 (0.5 to 7) | 2.08 (1 to 4.08) |
| Cycle 1/Day 22 (n=9, 12, 9, 15) | 1.98 (1 to 7) | 2.06 (0.95 to 4.25) | 2 (0.67 to 7) | 2 (0 to 7.05) |
Maximum observed plasma concentration following drug administration was calculated from the raw plasma concentration time data.
| nanograms/millitres(ng/mL) | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 |
|---|---|---|---|---|
| Cycle 1/Day 1 (n=11, 15, 10, 17) | 191.18 ± 82.464 | 246.39 ± 211.034 | 642.5 ± 486.709 | 618.88 ± 403.466 |
| Cycle 1/Day 22 (n=9, 12, 9, 15) | 769.22 ± 496.021 | 944.17 ± 553.395 | 1122 ± 736.862 | 1930 ± 677.949 |
ORR was determined in the participants with mutations on Hh gene (Hh positive) and the participants without mutations on Hh gene (Hh negative).
| % pediatric Hh + responders | Pediatric Participants |
|---|---|
| Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status | 66.7 |
Duration of overall response (complete response (CR) or partial response (PR)) was calculated for those participants whose best overall response was CR or PR. The start date was the date of the first documented tumor response (CR or PR) and the end date was the date of the event defined as the first documented progression or death due to underlying cancer or after the same treatment line. If a participant did not have a progression or death, the duration of response was censored at the date of last adequate tumor assessment in that treatment line.
| months | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| Duration of Response by Treatment | — | 7 (7 to 7) | 8.1 (8.1 to 8.1) | — | 4.86 (4.6 to 8.7) |
The tumor response to the sonidegib treatment was measured by ORR. The ORR was defined as the percentage of participants with partial response or complete response as their best overall response. Participants with stable disease, progressive disease tumor assessment were considered as non-responders. Response evaluation criteria was gadolinium chelate-enhanced brain tumor magnetic resonance imaging (Gd-MRI) for Medulloblastoma and central nervous system (CNS) tumors and response evaluation criteria in solid tumors (RECIST) version 1.0 for non-CNS tumors assessed by MRI. Complete Response (CR), Progressive Disease (PD) and Incomplete Response/Stable Disease (SD) were defined as disappearance of all non-target lesions, unequivocal progression of existing non-target lesions and Neither CR nor PD, respectively.
| Percentage of participants | Pediatric Participants | Adult Participants |
|---|---|---|
| Complete response | 3.3 | 12.5 |
| Partial response | 0 | 6.3 |
| Stable disease | 8.3 | 37.5 |
| Progressive disease | 76.7 | 37.5 |
| Objective response rate | 3.3 | 18.8 |
Collected over Adverse Events are collected from First Participant First Visit (FPFV) until Last Participant Last Visit (LPLV), Week 73. All Adverse events are reported in this record from First Participant First Treatment until LPLV, Week 73.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pediatric Participants, LDE225 233 mg/m^2 | — | 5/11 (45.5%) | 11/11 (100%) |
| Pediatric Participants, LDE225 372 mg/m^2 | — | 8/16 (50%) | 16/16 (100%) |
| Pediatric Participants, LDE225 425 mg/m^2 | — | 4/11 (36.4%) | 11/11 (100%) |
| Pediatric Participants, LDE225 680 mg/m^2 | — | 14/22 (63.6%) | 21/22 (95.5%) |
| Adult Participants, LDE225 800 mg | — | 5/16 (31.3%) | 16/16 (100%) |
| Event | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/11 | 0/16 | 1/11 | 4/22 | 0/16 |
| HeadacheNervous system disorders | 1/11 | 2/16 | 1/11 | 4/22 | 0/16 |
| ConvulsionNervous system disorders | 0/11 | 1/16 | 0/11 | 3/22 | 0/16 |
| General Physical Health DeteriorationGeneral disorders | 1/11 | 2/16 | 0/11 | 0/22 | 0/16 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 0/11 | 0/16 | 0/11 | 0/22 | 2/16 |
| Vision BlurredEye disorders | 1/11 | 0/16 | 0/11 | 0/22 | 0/16 |
| DysphagiaGastrointestinal disorders | 0/11 | 0/16 | 1/11 | 0/22 | 1/16 |
| PainGeneral disorders | 0/11 | 0/16 | 0/11 | 2/22 | 0/16 |
| PyrexiaGeneral disorders | 0/11 | 0/16 | 1/11 | 0/22 | 0/16 |
| PneumoniaInfections and infestations | 0/11 | 0/16 | 1/11 | 0/22 | 0/16 |
| Event | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 5/11 | 9/16 | 7/11 | 15/22 | 2/16 |
| HeadacheNervous system disorders | 6/11 | 7/16 | 4/11 | 9/22 | 2/16 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 1/11 | 1/16 | 2/11 | 6/22 | 8/16 |
| NauseaGastrointestinal disorders | 5/11 | 4/16 | 3/11 | 8/22 | 4/16 |
| FatigueGeneral disorders | 5/11 | 7/16 | 3/11 | 6/22 | 1/16 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 2/11 | 4/16 | 5/11 | 2/22 | 4/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/11 | 1/16 | 5/11 | 1/22 | 3/16 |
| ConstipationGastrointestinal disorders | 1/11 | 6/16 | 4/11 | 3/22 | 2/16 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 2/11 | 6/16 | 4/11 | 0/22 | 0/16 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 2/16 | 4/11 | 2/22 | 0/16 |
The analysis was performed in full analysis set population, defined as all the participants who received at least one dose of sonidegib.
| Age, Customized(participants) | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg | Total |
|---|---|---|---|---|---|---|
| ≤ 10 years | 4 | 3 | 5 | 11 | 0 | 23 |
| >10 years to 17 years | 7 | 13 | 6 | 11 | 0 | 37 |
| 18-65 years | 0 | 0 | 0 | 0 | 16 | 16 |
| Sex: Female, Male(Participants) | Pediatric Participants, LDE225 233 mg/m^2 | Pediatric Participants, LDE225 372 mg/m^2 | Pediatric Participants, LDE225 425 mg/m^2 | Pediatric Participants, LDE225 680 mg/m^2 | Adult Participants, LDE225 800 mg | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 6 | 3 | 10 | 7 | 30 |
| Male | 7 | 10 | 8 | 12 | 9 | 46 |
The record gives a start of Feb 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib